Summary
The rationale behind using Iron chelation therapy is removing the increased iron burden specifically labile cell iron (LCI) to minimize production of reactive oxygen species (ROS) thereby decreasing cellular and organ damage. Patients most likely to benefit from chelation therapy include those with low or intermediate-1 IPSS risk MDS who have a long-life expectancy and are anticipated to receive more than 20 red blood cell transfusions and/or whose serum ferritin level is >1000 μg/L. Chelation therapy efficacy can be monitored by monitoring trends and levels of serum ferritin.
HeyReport estimates that the Iron Chelation Drug market size will grow from xxx Million USD in 2020 to xxxx Million USD by 2025, and with a CAGR of xx%. The base year considered for this report is 2019, and the market forecast is projected from 2021 to 2025.
In this report, HeyReport discusses the Global & China industrial policies, economic environment, and the impact of covid-19 on the Iron Chelation Drugindustry and its cost structure. Besides, this report covers the basic market dynamics, market size and companies competition data. In addition, the report also conducts basic market research on major product type, market end-use and regional trade.
Market Segment as follows:
Product Type Segmentation Includes
Deferoxamine
Deferiprone
Deferasirox
Application Segmentation Includes
Transfusional Iron Overload
NTDT Caused Iron Overload
Companies Includes
Apotex Inc. (Canada)
Cipla (India)
Novartis (Switzerland)
Sun Pharma (India)
Natco Pharma (India)
The main contents of the report including:
Section 1:
Product definition, type and application, Global & China market overview;
Section 2:
Global & China Market competition by company;
Section 3:
Global & China sales revenue, volume and price by type;
Section 4:
Global & China sales revenue, volume and price by application;
Section 5:
China export and import;
Section 6:
Company information, business overview, sales data and product specifications;
Section 7:
Industry chain and raw materials;
Section 8:
Industrial policies & economic environment
Section 9:
Conclusion.
For any other requirements, please feel free to contact HeyReport for customized contents.
Table of Contents
1 Market Overview
1.1 Market Segment Overview
1.1.1 Product Definition
1.1.2 Market by Type
1.1.2.1 Deferoxamine
1.1.2.2 Deferiprone
1.1.2.3 Deferasirox
1.1.3 Market by Application
1.1.3.1 Transfusional Iron Overload
1.1.3.2 NTDT Caused Iron Overload
1.2 Global & China Market Size & Forecast
1.2.1 Global Market (2015-2020 & 2021-2026)
1.2.2 China Market (2015-2020 & 2021-2026)
2 Global & China Market by Company
2.1 Global Sales by Company
2.2 China Sales by Company
3 Global & China Market by Type
3.1 Global Sales by Product Type
3.2 China Sales by Product Type
4 Global & China Market by Application
4.1 Global Sales by Application
4.2 China Sales by Application
5 China Trade
5.1 Export Overview
5.2 Import Overview
6 Key Companies List
6.1 Apotex Inc. (Canada)
6.1.1 Company Information
6.1.2 Product Specifications
6.1.3 Business Data (2015-2020) (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.2 Cipla (India)
6.2.1 Company Information
6.2.2 Product Specifications
6.2.3 Business Data (2015-2020) (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.3 Novartis (Switzerland)
6.3.1 Company Information
6.3.2 Product Specifications
6.3.3 Business Data (2015-2020) (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.4 Sun Pharma (India)
6.4.1 Company Information
6.4.2 Product Specifications
6.4.3 Business Data (2015-2020) (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
6.5 Natco Pharma (India)
6.5.1 Company Information
6.5.2 Product Specifications
6.5.3 Business Data (2015-2020) (Capacity, Sales Revenue, Volume, Price, Cost and Margin)
7 Industry Upstream
7.1 Industry Chain
7.2 Upstream Overview
8 Policies & Market Environment
8.1 Policies
8.1.1 Major Regions Policies
8.1.2 Policies in China
8.2 Market Environment
8.2.1 Porter's Five Forces
8.2.2 Impact of COVID-19
9 Research Conclusion